-
公开(公告)号:US20230089196A1
公开(公告)日:2023-03-23
申请号:US17800740
申请日:2021-02-19
申请人: Genmab B.V.
发明人: Ewald T.J. VAN DEN BREMER , Sipke SANGERS , Demelza WILLEMSZ , Richard G. HIBBERT , Rob N. DE JONG , Søren Skov JENSEN , Emil POULSEN
IPC分类号: G01N33/68
摘要: The invention relates to methods for the quantification of glycoproteins in a sample, comprising quantifying said glycoproteins by comparison with an internal standard, wherein said internal standard comprises variant forms of said glycoproteins, wherein said variant forms contain only core Asn-linked GlcNAc moieties.
-
公开(公告)号:US20210163619A1
公开(公告)日:2021-06-03
申请号:US16921154
申请日:2020-07-06
申请人: GENMAB B.V.
摘要: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
-
公开(公告)号:US20210230301A1
公开(公告)日:2021-07-29
申请号:US17012102
申请日:2020-09-04
申请人: GENMAB B.V.
发明人: Rob N. DE JONG , Frank BEURSKENS , Paul PARREN , Aran Frank LABRIJN , Janine SCHUURMAN , Arjen VLUG , Sandra VERPLOEGEN
摘要: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
-
公开(公告)号:US20150353636A1
公开(公告)日:2015-12-10
申请号:US14760135
申请日:2013-01-10
申请人: GENMAB B.V.
发明人: Paul PARREN , Frank BEURSKENS , Rob N. DE JONG , Sandra VERPLOEGEN , Aran Frank LABRIJN , Janine SCHUURMAN
CPC分类号: C07K16/283 , A61K39/3955 , A61K47/6849 , A61K51/1027 , A61K2039/505 , A61K2039/507 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K16/2896 , C07K16/36 , C07K16/40 , C07K19/00 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/90 , C07K2317/92 , C07K2319/30
摘要: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).
摘要翻译: 本文描述的是包含变体Fc结构域的多肽和相关抗体。 当多肽,抗体或抗体与细胞表面上的靶标,抗原或抗原结合时,变体Fc结构域提供稳定的Fc:Fc相互作用,从而提供改善的补体依赖性细胞毒性(CDC)。
-
-
-